Department of Cardiology, School of Medicine, Shahid Madani Hospital, Lorestan University of Medical Sciences, Lorestan, Iran.
Department of Emergency Medicine, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Cardiovasc Toxicol. 2024 Dec;24(12):1381-1394. doi: 10.1007/s12012-024-09924-8. Epub 2024 Oct 14.
Cancer patients may encounter the onset of cardiovascular disease due to tumor advancement or chemotherapy, commonly known as "cardiotoxicity." In this respect, the conventional chemotherapy treatment protocol involves a mixture of different medications. These medications can be detrimental to cardiac tissue, consequently exposing the patient to the possibility of irreversible cardiac injury. The enhancement of oxidative stress and inflammation is an important mechanism of chemotherapeutic agents for developing cardiotoxicity. Regarding their dual pro- and anti-inflammatory functions, platelets can significantly influence the progression or suppression of cardiotoxicity. Therefore, the expression of platelet activatory markers can serve as valuable prognostic indicators for cardiotoxicity. The primary objective of this study is to examine the significance of platelets in cardiotoxicity and explore potential strategies that could effectively target malignant cells while minimizing their cytotoxic impact, such as cardiotoxicity and thrombosis.
癌症患者可能会因肿瘤进展或化疗而出现心血管疾病,通常称为“心脏毒性”。在这方面,传统的化疗治疗方案涉及不同药物的混合。这些药物可能对心脏组织有害,因此使患者面临不可逆转的心脏损伤的可能性。氧化应激和炎症的增强是化疗药物引起心脏毒性的一个重要机制。关于血小板的双重促炎和抗炎功能,它们可以显著影响心脏毒性的进展或抑制。因此,血小板活化标志物的表达可以作为心脏毒性的有价值的预后指标。本研究的主要目的是研究血小板在心脏毒性中的意义,并探索能够有效靶向恶性细胞的潜在策略,同时最大限度地减少其细胞毒性影响,如心脏毒性和血栓形成。